Follow

Submissions from 2022

Link

The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021., Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, Andrew Futreal, Omid Hamid, Theresa LaVallee, Michael A Postow, Igor Puzanov, Jeffrey Sosman, Bernard A Fox, and Patrick Hwu

Link

Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial., Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J Harding, Stella K Kim, Iris H C Miedema, Danielle J Vugts, Marc C Huisman, Gerben J C Zwezerijnen, Guus A M S van Dongen, Catharina W Menke-van der Houven van Oordt, Song Wang, Tam Dang, Ivan A Zein, Olga Vasiljeva, Susan K Lyman, Virginia Paton, Alison Hannah, and Joyce F Liu

Link

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer., Brie Chun, Joanna Pucilowska, Shu-Ching Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A Fields, Valerie Conrad, Mark Schmidt, Walter Urba, Alison Conlin, Heather L McArthur, and David B Page

Phase 1 study of SEA-TGT, a human, nonfucosylated monoclonal antibody directed to TIGIT with enhanced immune effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress), D Davar, Rachel E Sanborn, and See full list of authors in comments

Link

PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors., Rebekka Duhen, Olivier Fesneau, Kimberly Samson, Alexandra K Frye, Michael Beymer, Venkatesh Rajamanickam, David Ross, Eric Tran, Brady Bernard, Andrew D Weinberg, and Thomas Duhen

Link

Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers., Robert S. Epstein, Roshanthi Weerasinghe, Amy S. Parrish, JoAnn Krenitsky, Rachel E Sanborn, and Tehseen Salimi

Link

Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)., Robert L Ferris, Yael Flamand, Gregory S Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J Garcia, Christine H Chung, Maura L Gillison, Umamaheswar Duvvuri, Bert W O'Malley, Enver Ozer, Giovana R Thomas, Wayne M Koch, Neil D Gross, Richard Bryan Bell, Nabil F Saba, Miriam Lango, Eduardo Méndez, and Barbara Burtness

Identification of a subset of tumor-reactive CD8 TIL expressing NKG2A in HNSCC and CRC, O Fesneau, K Samson, V Rajamanickam, D Ross, and Thomas Duhen

Link

The Human Tumor Atlas Network's beginning steps toward the future of collaborative multi-omic discovery., David B Page

Link

Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases., David B Page, Kathryn Beal, Stefanie N Linch, Kateri Spinelli, Micaela Rodine, Darragh Halpenny, Shanu Modi, Sujata Patil, Robert J Young, Thomas Kaley, Taha Merghoub, David Redmond, Phillip Wong, Christopher A Barker, Adi Diab, Larry Norton, and Heather L McArthur

Link

Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8, Annah S Rolig, Daniel Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, and William L. Redmond

Link

Neoantigen-specific CD4 + T cells in human melanoma have diverse differentiation states and correlate with CD8 + T cell, macrophage, and B cell function, Joshua R Veatch, Sylvia M Lee, Carolyn Shasha, Naina Singhi, Julia L Szeto, Ata S Moshiri, Teresa S Kim, Kimberly Smythe, Paul Kong, Matthew Fitzgibbon, Brenda Jesernig, Shailender Bhatia, Scott S Tykodi, Evan T Hall, David R Byrd, John A Thompson, Venu G Pillarisetty, Thomas Duhen, A McGarry Houghton, Evan Newell, Raphael Gottardo, and Stanley R Riddell

T Cell Agonists, Andrew D Weinberg

Link

Current Clinical Trial Landscape of OX40 Agonists., Rashi Yadav and William L. Redmond

Submissions from 2021

Link

Listeria monocytogenes-infected human monocytic derived dendritic cells activate Vγ9Vδ2 T cells independently of HMBPP production., Alejandro F Alice, Gwen Kramer, Shelly Bambina, Keith S Bahjat, Michael J Gough, and Marka R Crittenden

Link

Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma., Robert H I Andtbacka, Brendan Curti, Gregory A Daniels, Sigrun Hallmeyer, Eric D Whitman, Jose Lutzky, Lynn E Spitler, Karl Zhou, Praveen K Bommareddy, Mark Grose, Meihua Wang, Cai Wu, and Howard L Kaufman

Link

Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy)., Paolo A Ascierto, Carlo Bifulco, Fortunato Ciardiello, Sandra Demaria, Leisha A Emens, Robert Ferris, Silvia C Formenti, Jerome Galon, Samir N Khleif, Tomas Kirchhoff, Jennifer McQuade, Kunle Odunsi, Akash Patnaik, Chrystal M Paulos, Janis M Taube, John Timmerman, Bernard A Fox, Patrick Hwu, and Igor Puzanov

Link

The State of Melanoma: Emergent Challenges and Opportunities., Michael B Atkins, Clara Curiel-Lewandrowski, David E Fisher, Susan M Swetter, Hensin Tsao, Julio A Aguirre-Ghiso, Maria S Soengas, Ashani T Weeraratna, Keith T Flaherty, Meenhard Herlyn, Jeffrey A Sosman, Hussein A Tawbi, Anna C Pavlick, Pamela B Cassidy, Sunandana Chandra, Paul B Chapman, Adil Daud, Zeynep Eroglu, Laura K Ferris, Bernard A Fox, Jeffrey E Gerhsenwald, Geoffrey T Gibney, Douglas Grossman, Brent A Hanks, Douglas Hanniford, Eva Hernando, Joanne M Jeter, Douglas B Johnson, Samir N Khleif, John M Kirkwood, Sancy A Leachman, Darren Mays, Kelly C Nelson, Vernon K Sondak, Ryan J Sullivan, and Glenn Merlino

Link

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134, Michael B. Atkins, Brendan Curti, and See full list of authors in comments

Link

Arginase therapy combines effectively with checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth., Mark D Badeaux, Annah S Rolig, Giulia Agnello, Danlee Enzler, Melissa Kasiewicz, Leslie Priddy, Jason F Wiggins, Alexander Muir, Mark R Sullivan, Jessica Van Cleef, Christopher Daige, Matthew G Vander Heiden, Venkatesh Rajamanickam, James Wooldridge, William L. Redmond, and Scott W Rowlinson

PDF

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy., Peng Bai, Yongzheng Li, Qiuping Zhou, Jiaqi Xia, Peng-Cheng Wei, Hexiang Deng, Min Wu, Sanny K Chan, John W Kappler, Yu Zhou, Eric Tran, Philippa Marrack, and Lei Yin

PDF

SARS-CoV-2 antibodies detected in human breast milk postvaccination, Jill K. Baird, Shawn M. Jensen, Walter Urba, Bernard A Fox, and Jason R Baird

Link

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response., Joshua Bauml, Byoung Chul Cho, Rachel E Sanborn, and See full author list in comments

10. Dendritic cell migration is required for the immunological responsiveness of tumors to radiation therapy, TC Blair, G Kramer, S Bambina, A Dowdell, AF Alice, Brian D. Piening, Marka R Crittenden, and MJ Gough

Link

165 Generating enhanced tumor infiltrating lymphocytes through microfluidic cell squeezing, Devin Bridgen, Andrew D Weinberg, and See full list of authors in comments

Link

Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies., Samantha Brown, Jessica A Lavery, Ronglai Shen, Axel S Martin, Kenneth L Kehl, Shawn M Sweeney, Eva M Lepisto, Hira Rizvi, Caroline G McCarthy, Nikolaus Schultz, Jeremy L Warner, Ben Ho Park, Philippe L Bedard, Gregory J Riely, Deborah Schrag, Katherine S Panageas, AACR Project GENIE Consortium, Walter Urba, Brady Bernard, Brian D. Piening, and Carlo Bifulco

Link

A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors., Howard A. Burris III, Alexander I. Spira, and Matthew H Taylor

Link

Portable air-fed cold atmospheric plasma device for postsurgical cancer treatment., Guojun Chen, Zhitong Chen, Zejun Wang, Richard Obenchain, Di Wen, Hongjun Li, Richard E Wirz, and Zhen Gu

Link

Impact of new cancer therapies on outpatient treatment delivery for colorectal cancer: A population-based study., Leo Chen, Caroline H Speers, Winson Y Cheung, John J Spinelli, and Hagen F Kennecke

Link

Secondary Correction of Midface Fractures., Jonathan Chodroff, Nadir Elias, Michael Whitcomb, Cong Vo, and Richard Bryan Bell

Link

94 Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC), Brie Chun, Joanna Pucilowska, Shu-Ching Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul Fields, Valerie Conrad, Mark Schmidt, Walter Urba, Alison Conlin, Heather McArthur, and David B Page

Link

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2., Joseph I Clark, Brendan Curti, Elizabeth J Davis, Howard Kaufman, Asim Amin, Ajjai Alva, Theodore F Logan, Ralph Hauke, Gerald P Miletello, Ulka Vaishampayan, Douglas B Johnson, Richard L White, Peter H Wiernik, and Janice P Dutcher

Link

Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings., Roger B. Cohen, George E. Peoples, Rachel E Sanborn, and See list of authors in comments

Link

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors., Kevin Conlon, Dionysios C Watson, Thomas A Waldmann, Antonio Valentin, Cristina Bergamaschi, Barbara K Felber, Cody J Peer, William D Figg, E Lake Potter, Mario Roederer, Douglas G McNeel, John A Thompson, Sumati Gupta, Rom Leidner, Andrea Wang-Gillam, Nehal S Parikh, Debby Long, Sema Kurtulus, Lang Ho Lee, Niladri Roy Chowdhury, Florent Bender, and George N Pavlakis

Link

Combinations of stereotactic radiotherapy and immune checkpoint inhibition: Translational analyses, Marka R Crittenden

Integrating Radiation Therapy with Immunotherapy, Marka R Crittenden

Link

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor., Brendan D Curti, Yoshinobu Koguchi, Rom S Leidner, Annah S Rolig, Elizabeth R Sturgill, Zhaoyu Sun, Yaping Wu, Venkatesh Rajamanickam, Brady Bernard, Ian Hilgart-Martiszus, Christopher B Fountain, George Morris, Noriko Iwamoto, Takashi Shimada, ShuChing Chang, Peter G Traber, Eliezer Zomer, J Rex Horton, Harold Shlevin, and William L Redmond

Link

381 Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study, Brendan Curti and See full list of authors in comments

Link

474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress), Diwakar Davar, Rachel E Sanborn, and See full list of authors in comments

Link

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma., Adi Diab, Scott S Tykodi, Gregory A Daniels, Michele Maio, Brendan D Curti, Karl D Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander I Spira, Daniel C Cho, Shanhong Guan, Erika Puente, Tuan Nguyen, Ute Hoch, Sue L Currie, Wei Lin, Mary A Tagliaferri, Jonathan Zalevsky, Mario Sznol, and Michael E Hurwitz

Link

First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors., Khanh T Do, Laura Quan Man Chow, Karen Reckamp, Rachel E Sanborn, Howard Burris, Francisco Robert, D Ross Camidge, Conor E Steuer, John H Strickler, Amy Weise, Jennifer M Specht, Martin Gutierrez, Peter Haughney, Shawna Hengel, Christina Louise Derleth, and Timothy A Yap

Link

Cancer case trends following the onset of the COVID-19 pandemic: A community-based observational study with extended follow-up., Charles W Drescher, Adam J Bograd, Shu-Ching Chang, Roshanthi Weerasinghe, Ann Vita, and Richard Bryan Bell

Link

The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation., Shaan Dudani, Horia Marginean, Joanna Gotfrit, Patricia A Tang, Jose Gerard Monzon, Kristopher Dennis, Hagen F Kennecke, Erin D Powell, Sam Babak, Winson Y Cheung, and Michael M Vickers

PDF

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells., Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K Frye, Eric Tran, Venkatesh Rajamanickam, Shu-Ching Chang, Yoshinobu Koguchi, Carlo Bifulco, Brady Bernard, Rom Leidner, Brendan Curti, Bernard A Fox, Walter Urba, Richard Bryan Bell, and Andrew D Weinberg

Link

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer., Leisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L Disis, Margaret E Gatti-Mays, Alice Y Ho, Kevin Kalinsky, Heather L McArthur, Elizabeth A Mittendorf, Rita Nanda, David B Page, Hope S Rugo, Krista M Rubin, Hatem Soliman, Patricia A Spears, Sara M Tolaney, and Jennifer K Litton

Link

Enhancing the generation of Eomeshi CD8+ T cells augment the efficacy of OX40- and CTLA-4-targeted immunotherapy., Dana A Emerson, Annah S Rolig, and William L. Redmond

Link

383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695, Pablo Fernandez-Penas, Carmen Ballesteros-Merino, Shawn M. Jensen, Bernard A Fox, and See full list of authors in comments

Link

Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311)., Robert L. Ferris, Yael Flammand, Richard Bryan Bell, and See list of authors in comments

Link

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial., Robert L Ferris, William C Spanos, Rom Leidner, Anthony Gonçalves, Uwe M Martens, Chrisann Kyi, William Sharfman, Christine H Chung, Lot A Devriese, Helene Gauthier, Simon I Chiosea, Lazar Vujanovic, Janis M Taube, Julie E Stein, Jun Li, Bin Li, Tian Chen, Adam Barrows, and Suzanne L Topalian

Evaluating the cancer surfaceome: a possible strategy to identify targets and monitor immunity, Bernard A Fox

Exploiting Autophagy and the Ubiquitin Pathway to Educate the Immune System and Improve Cancer Immunotherapy, Bernard A Fox

Translation: An Iterative and Team Process – Our Path to the Development of Triplet Cancer Immunotherapy, Bernard A Fox

Link

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study., Justin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S Baik, Robert C Doebele, Philippe A Cassier, Gilberto Lopes, Daniel S W Tan, Elena Garralda, Luis G Paz-Ares, Byoung Chul Cho, Shirish M Gadgeel, Michael Thomas, Stephen V Liu, Matthew H Taylor, Aaron S Mansfield, Viola W Zhu, Corinne Clifford, Hui Zhang, Michael Palmer, Jennifer Green, Christopher D Turner, and Vivek Subbiah

Link

SGNTGT-001: A phase 1 study of SEA‑TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress)., Elenda Garralda, Rachel E Sanborn, and See list of authors in comments

Link

The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy., Nikesha Gilmore, Supriya Mohile, Lianlian Lei, Eva Culakova, Mostafa Mohamed, Allison Magnuson, Kah Poh Loh, Ronald Maggiore, Elizabeth Belcher, Alison Conlin, Lora Weiselberg, Mary Ontko, and Michelle Janelsins

Link

Outreach: Preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the nonuniversity setting., John E Godwin, Bassam I. Mattar, and See list of authors in comments

Link

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL), John E Godwin and See full list of authors in comments

Link

Assessing the risk of thromboembolism in cancer patients receiving immunotherapy., Abhishek Goel, Arjun Khorana, Thomas Kartika, Sonia Gowda, Derrick L Tao, Rajat Thawani, and Joseph J Shatzel

Link

Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature., Jason D Goldman, George Diaz, and Walter Urba

The Dynamics of pre-existing T cells in tumors and the effects of radiation therapy, M Gough

Link

Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer., Andrew J Gunderson, Venkatesh Rajamanickam, Cynthia Bui, Brady Bernard, Joanna Pucilowska, Carmen Ballesteros-Merino, Mark Schmidt, Kayla McCarty, Michaela Philips, Brian D. Piening, Christopher Dubay, Terry R Medler, Phillipa Newell, Paul D Hansen, Eric Tran, Ephraim Tang, Carlo Bifulco, Marka R Crittenden, Michael J. Gough, and Kristina H Young

Link

LB180 - Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation, Kevin J. Harrington, Francesca Aroldi, Joseph J. Sacco, Mohammed M. Milhem, Brendan Curti, Ari M. Vanderwalde, Scott Baum, Adel Samson, Anna C. Pavlick, Jason A. Chesney, Jiaxin Niu, Terence D. Rhodes, Tawnya L. Bowles, Robert Conry, Anna Olsson-Brown, Douglas E. Laux, Pablo Nenclares, Lavita Menezes, Alex Deterding, Victoria Roulstone, Joan Kyula, Suzanne Thomas, Praveen K. Bommareddy, Selda Samakoglu, Andrea Pirzkall, Robert S. Coffin, and Mark R. Middleton

Link

First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers., Alan L. Ho, Marshall R. Posner, and Rom Leidner

Link

Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors., David S Hong, Olivier Rixe, Vi K Chiu, Patrick M Forde, Tomislav Dragovich, Yanyan Lou, Asha Nayak-Kapoor, Rom Leidner, James N Atkins, Agron Collaku, Floyd E Fox, Margaret A Marshall, and Anthony J Olszanski

Link

Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101., Antonio Jimeno, Joaquina C. Baranda, Matthew H Taylor, and See all authors in comments

Link

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies., Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E Sanborn, Javier Garcia-Corbacho, Valentina Boni, Mark Stroh, Alison L Hannah, Song Wang, Henry Castro, and Alexander Spira

Link

Treatment dependent improvements in survival of stage 2/3 rectal cancer patients treated with trimodality therapy between 2006-2016, an NCDB analysis., Hagen F Kennecke, Henry T. Bahnson, and See list of authors in comments

Link

CCTG CO.28 primary endpoint analysis: Neoadjuvant chemotherapy, excision and observation for early rectal cancer, the NEO trial., Hagen F Kennecke, Carl J. Brown, and See full list of authors in comments

Link

Noninvasive biomarkers for prediction and diagnosis of heart transplantation rejection., Yeraz Khachatoorian, Vahe Khachadourian, Eleanor Chang, Erick R Sernas, Elaine F Reed, Mario Deng, Brian D. Piening, Alexandre C Pereira, Brendan Keating, and Martin Cadeiras

Link

"Custom" Plate in a Day-Accurate Predictive Hole Fabrication Using Point-of-Care 3-Dimensional Printing., Baber Khatib, Marcus Couey, Ashish Patel, Allen C Cheng, and Richard Bryan Bell

Link

Updates in Management of Craniomaxillofacial Gunshot Wounds and Reconstruction of the Mandible., Baber Khatib, Savannah Gelesko, Melissa Amundson, Allen Cheng, Ashish Patel, Tuan Bui, Eric J Dierks, and R Bryan Bell

Link

A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy., Isaac Kim, Venkatesh Rajamanickam, Brady Bernard, Brie Chun, Yaping Wu, Maritza Martel, Zhaoyu Sun, William L Redmond, Katherine Sanchez, Reva Basho, Heather McArthur, and David B Page

Link

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab., Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brendan Curti, Walter Urba, Brian D. Piening, and William L. Redmond

Link

Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study., Matthew H Kulke, Hagen F Kennecke, Kris Murali, and Vijay N Joish

Link

Unaltered IL-2 encapsulated in acoustically active lipid microspheres for systemic but targeted microdose delivery to tumor microenvironment., Clayton Larsen, Llew Keltner, William L. Redmond, and Rhodemann Li

Link

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study., Chung-Han Lee, Amishi Yogesh Shah, Drew Rasco, Arpit Rao, Matthew H Taylor, Christopher Di Simone, James J Hsieh, Alvaro Pinto, David R Shaffer, Regina Girones Sarrio, Allen Lee Cohn, Nicholas J Vogelzang, Mehmet Asim Bilen, Sara Gunnestad Ribe, Musaberk Goksel, Øyvind Krohn Tennøe, Donald Richards, Randy F Sweis, Jay Courtright, Daniel Heinrich, Sharad Jain, Jane Wu, Emmett V Schmidt, Rodolfo F Perini, Peter Kubiak, Chinyere E Okpara, Alan D Smith, and Robert J Motzer

Link

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma., Rom Leidner, Marka Crittenden, Kristina Young, Hong Xiao, Yaping Wu, Marcus A Couey, Ashish A Patel, Allen C Cheng, Amber L Watters, Carlo Bifulco, George Morris, Lessli Rushforth, Shorin Nemeth, Walter J Urba, Michael Gough, and R Bryan Bell

Link

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates., John B Liao, William R Gwin, Renata R Urban, Katie M Hitchcock-Bernhardt, Andrew L Coveler, Doreen M Higgins, Jennifer S Childs, Hania N Shakalia, Ron E Swensen, Sasha E Stanton, Anna V Tinker, Tanya A Wahl, Richard G Ancheta, Kathryn F McGonigle, James Y Dai, Mary L Disis, and Barbara A Goff

Link

Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis., Hongjun Li, Zejun Wang, Zhaowei Chen, Tianyuan Ci, Guojun Chen, Di Wen, Ruoxin Li, Jinqiang Wang, Huan Meng, R Bryan Bell, Zhifeng Gu, Gianpietro Dotti, and Zhen Gu

Link

Effects of yoga, cognitive behavioral therapy, and a behavioral placebo on sleep: A nationwide multicenter phase III RCT in cancer survivors., Po-Ju Lin, Charles E. Heckler, Alison Conlin, and See full list of authors in comments

Link

Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen., Siyu Liu, Emily Bellile, Ariane Nguyen, Katie Zarins, Nisha D'Silva, Laura Rozek, Gregory T Wolf, Maureen A Sartor, INSPIRE Trial Clinical Investigators, and Richard Bryan Bell

Link

Caregiver-Oncologist Prognostic Concordance, Caregiver Mastery, and Caregiver Psychological Health and Quality of Life., Kah Poh Loh, Mostafa R Mohamed, Sindhuja Kadambi, Eva Culakova, Huiwen Xu, Allison Magnuson, Marie Flannery, Paul R Duberstein, Ronald M Epstein, Colin McHugh, Ryan D Nipp, Kelly M Trevino, Chandrika Sanapala, Bianca A Hall, Beverly Canin, Arlene A Gayle, Alison Conlin, James Bearden, and Supriya G Mohile

Link

Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!, Michele Maio, Christian Blank, Andrea Necchi, Anna Maria Di Giacomo, Ramy Ibrahim, Michael Lahn, Bernard A Fox, R Bryan Bell, Giampaolo Tortora, and Alexander M M Eggermont

Link

A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation., Michele Maio, Michael Lahn, Anna Maria Di Giacomo, Alessia Covre, Luana Calabrò, Ramy Ibrahim, Bernard Fox, and Siena Think Tank

Link

354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study, Vicky Makker, Matthew H Taylor, and See full list of authors in comments

Link

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE., E P Mamounas, M Untch, M S Mano, C-S Huang, C E Geyer, G von Minckwitz, N Wolmark, X Pivot, S Kuemmel, M P DiGiovanna, B Kaufman, G Kunz, A K Conlin, J C Alcedo, T Kuehn, I Wapnir, A Fontana, J Hackmann, J Polikoff, M Saghatchian, A Brufsky, Y Yang, M Zimovjanova, T Boulet, H Liu, D Tesarowski, L H Lam, C Song, M Smitt, and S Loibl

Link

A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors., Aaron S Mansfield, David S Hong, Christine L Hann, Anna F Farago, Himisha Beltran, Saiama N Waqar, Andrew E Hendifar, Lowell B Anthony, Matthew H Taylor, Alan H Bryce, Scott T Tagawa, Karl Lewis, Jiaxin Niu, Christine H Chung, James M Cleary, Michael Rossi, Carrianne Ludwig, Ricardo Valenzuela, Yan Luo, and Rahul Aggarwal

Link

Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer., Sebastian Marwitz, Carmen Ballesteros-Merino, Shawn M. Jensen, Martin Reck, Christian Kugler, Sven Perner, Daniel Drömann, Torsten Goldmann, and Bernard A Fox

Link

Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report., Altaf Mohammed, Roderick H Dashwood, Sally Dickinson, Mary L Disis, Elizabeth M Jaffee, Bryon D Johnson, Samir N Khleif, Michael N Pollak, Jeffrey Schlom, Robert H Shoemaker, Sasha Stanton, Georg T Wondrak, Ming You, Hao Zhu, and Mark Steven Miller

Link

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)., Kathleen N Moore, Michael Bookman, Jalid Sehouli, Austin Miller, Charles Anderson, Giovanni Scambia, Tashanna Myers, Cagatay Taskiran, Katina Robison, Johanna Mäenpää, Lyndsay Willmott, Nicoletta Colombo, Jessica Thomes-Pepin, Michalis Liontos, Michael A Gold, Yolanda Garcia, Sudarshan K Sharma, Christopher J Darus, Carol Aghajanian, Aikou Okamoto, Xiaohua Wu, Rustem Safin, Fan Wu, Luciana Molinero, Vidya Maiya, Victor K Khor, Yvonne G Lin, and Sandro Pignata

Link

HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells., Tamson V Moore, Gina M Scurti, Matthew DeJong, Siao-Yi Wang, Annika V Dalheim, Courtney R Wagner, Kelli A Hutchens, Jodi J Speiser, Constantine V Godellas, Chris Fountain, Jessica Fleser, Tarsem Moudgil, Mallory Thomas, David Murray, Brendan D Curti, Joseph I Clark, Bernard A Fox, and Michael I Nishimura

Link

85 Detection of human angiotensin-converting enzyme 2 receptor (hACE2R) on human cancer cell lines, Tarsem Moudgil, Bernard A Fox, and Hong-Ming Hu

Link

Induction of ADAM10 by RT drives fibrosis, resistance, and EMT in pancreatic cancer., Adam C Mueller, Miles Piper, Andrew Goodspeed, Shiv Bhuvane, Jason S Williams, Shilpa Bhatia, Andy V Phan, Benjamin Van Court, Kathryn L Zolman, Brisa Peña, Ayman J Oweida, Sara Zakem, Cheryl Meguid, Michael W Knitz, Laurel Darragh, Thomas E Bickett, Jacob Gadwa, Luisa Mestroni, Matthew R G Taylor, Kimberly R Jordan, Peter Dempsey, M Scott Lucia, Martin D McCarter, Marco Del Chiaro, Wells A Messersmith, Richard D Schulick, Karyn A Goodman, Michael J. Gough, Casey S Greene, James C Costello, Antonio Galvao Neto, David Lagares, Kirk C Hansen, Adrie Van Bokhoven, and Sana D Karam

Link

509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer, Aung Naing, Brendan Curti, and See full list of authors in comments

Link

Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report, Jasmine Naru, John E Godwin, and See full list of authors in comments

Link

1665 - QuPath versus InForm: Digital image analysis of multiplex immunofluorescence (mIF) tumor-infiltrating lymphocyte (TIL) outcomes in an immunotherapy clinical trial, Benjamin Nikitin, Brie Chun, Isaac Kim, William L. Redmond, Katherine Sanchez, Zhaoyu Sun, Yaping Wu, and David B Page

Link

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial., Makoto Nishio, Fabrice Barlesi, Howard West, Simon Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome Goldschmidt, Silvia Novello, Francisco Orlandi, Rachel E Sanborn, Zsuzsanna Szalai, Grigoriy Ursol, Diana Mendus, Lijia Wang, Xiaohui Wen, Mark McCleland, Tien Hoang, See Phan, and Mark A Socinski

Link

Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study, Yishai Ofran, John E Godwin, and See full list of authors in comments

Link

Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia., Megan Othus, Guillermo Garcia-Manero, John E Godwin, James Weick, Derek Stirewalt, Frederick Appelbaum, Harry Erba, and Elihu Estey

Teaming up to Finish Triple-Negative Breast Cancer, David B Page